Literature DB >> 10718779

The effect of NAT2 genotype and gender on the metabolism of caffeine in nonsmoking subjects.

M R Welfare1, M F Bassendine, A K Daly.   

Abstract

AIMS: To establish whether gender or N-acetyltransferase 2 (NAT2) genotype influence the urinary 17 U+17X/137X ratio after dosing with caffeine.
METHODS: Ninety-two nonsmoking individuals underwent caffeine phenotyping. NAT2 genotype was determined by the polymerase chain reaction followed by a restriction digest (PCR-RFLP).
RESULTS: The median ratio for urinary 17 U+17X/137X was 6.7 (range 1.45-18. 65). 55% of subjects were slow acetylators. Gender did not affect the metabolic ratio or NAT2 genotype. Mean 17 U+17X/137X ratio differed between fast (6.75) and slow (8.69) acetylators (95% CI for the difference, 0.32-3.56).
CONCLUSIONS: The findings are further evidence that the 17 U+17X/137X urinary ratio is not a robust measure of CYP1A2 activity. A possible mechanism by which the ratio might be influenced by NAT2 genotype is suggested.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10718779      PMCID: PMC2014918          DOI: 10.1046/j.1365-2125.2000.00130.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  9 in total

1.  A population and family study of CYP1A2 using caffeine urinary metabolites.

Authors:  A Catteau; Y C Bechtel; N Poisson; P R Bechtel; C Bonaïti-Pellie
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

2.  Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva.

Authors:  U Fuhr; K L Rost
Journal:  Pharmacogenetics       Date:  1994-06

3.  Relationship between acetylator status, smoking, and diet and colorectal cancer risk in the north-east of England.

Authors:  M R Welfare; J Cooper; M F Bassendine; A K Daly
Journal:  Carcinogenesis       Date:  1997-07       Impact factor: 4.944

4.  Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment.

Authors:  A Rostami-Hodjegan; S Nurminen; P R Jackson; G T Tucker
Journal:  Pharmacogenetics       Date:  1996-04

5.  Detailed modelling of caffeine metabolism and examination of the CYP1A2 gene: lack of a polymorphism in CYP1A2 in Caucasians.

Authors:  M R Welfare; M Aitkin; M F Bassendine; A K Daly
Journal:  Pharmacogenetics       Date:  1999-06

6.  Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene.

Authors:  M Nakajima; T Yokoi; M Mizutani; S Shin; F F Kadlubar; T Kamataki
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1994 Jul-Aug       Impact factor: 4.254

7.  N-acetyltransferase polymorphism. Comparison of phenotype and genotype in humans.

Authors:  D Hickman; E Sim
Journal:  Biochem Pharmacol       Date:  1991-08-08       Impact factor: 5.858

8.  Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites.

Authors:  M A Butler; N P Lang; J F Young; N E Caporaso; P Vineis; R B Hayes; C H Teitel; J P Massengill; M F Lawsen; F F Kadlubar
Journal:  Pharmacogenetics       Date:  1992-06

9.  Rapid metabolic phenotypes for acetyltransferase and cytochrome P4501A2 and putative exposure to food-borne heterocyclic amines increase the risk for colorectal cancer or polyps.

Authors:  N P Lang; M A Butler; J Massengill; M Lawson; R C Stotts; M Hauer-Jensen; F F Kadlubar
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1994-12       Impact factor: 4.254

  9 in total
  4 in total

1.  Caffeine, selected metabolic gene variants, and risk for neural tube defects.

Authors:  Rebecca J Schmidt; Paul A Romitti; Trudy L Burns; Jeffrey C Murray; Marilyn L Browne; Charlotte M Druschel; Richard S Olney
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2010-07

2.  Salivary caffeine metabolic ratio in alcohol-dependent subjects.

Authors:  Veerapol Kukongviriyapan; Laddawan Senggunprai; Auemduan Prawan; Danu Gaysornsiri; Upa Kukongviriyapan; Jareerat Aiemsa-Ard
Journal:  Eur J Clin Pharmacol       Date:  2004-03-12       Impact factor: 2.953

3.  Female sex and discontinuation of isoniazid due to adverse effects during the treatment of latent tuberculosis.

Authors:  April C Pettit; James Bethel; Yael Hirsch-Moverman; Paul W Colson; Timothy R Sterling
Journal:  J Infect       Date:  2013-07-08       Impact factor: 6.072

Review 4.  Incorporating children's toxicokinetics into a risk framework.

Authors:  Gary Ginsberg; William Slikker; James Bruckner; Babasaheb Sonawane
Journal:  Environ Health Perspect       Date:  2004-02       Impact factor: 9.031

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.